Kiniksa Pharmaceuticals Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.0% | -1.3% | +4.4% | +2.4% | +4.5% | +3.2% | +10.3% | +7.7% | +7.2% | +8.1% | +8.6% | |
| – | +7.9% | -2.1% | +11.2% | +3.4% | +6.6% | +7.3% | +18.1% | +13.1% | +10.9% | +12.7% | +12.5% | |
| – | -8.4% | +30.7% | -29.6% | -1.9% | +88.5% | -14.4% | +22.2% | -8.9% | -5.3% | +14.7% | -7.5% | |
| – | +2.6% | +3.5% | +2.4% | +2.3% | +8.9% | +10.1% | +14.7% | +14.4% | +17.6% | +13.0% | +12.4% | |
| – | +599.3% | -24.8% | +27.9% | +21.7% | +67.6% | -4.0% | -20.4% | +62.1% | -69.9% | +48.9% | +1.1% | |
| – | +21.7% | -12.4% | +27.8% | -17.7% | -8.1% | -16.3% | +118.3% | -14.1% | +32.6% | +33.2% | -3.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.4% | -1.4% | -1.5% | -1.5% | -1.5% | -1.5% | -1.6% | -1.6% | -1.6% | -1.6% | -1.7% | |
| – | +12.2% | +0.3% | +22.3% | +10.2% | +20.1% | -0.2% | +17.1% | +6.5% | +10.8% | +12.0% | +10.2% | |
| – | +19.1% | +0.9% | +31.3% | +13.8% | +4.9% | -3.3% | +21.1% | +4.9% | +12.6% | +12.5% | +9.3% | |
| – | -2.6% | +1.2% | -8.5% | -2.6% | -1.9% | +15.0% | +10.0% | +6.9% | +10.8% | +6.1% | +26.6% | |
| – | +714.8% | -31.7% | +31.3% | +12.6% | -75.5% | -2.8% | +351.9% | -31.3% | -67.0% | +1,103.3% | -49.2% | |
| – | +8.3% | -1.6% | +0.7% | +0.4% | +0.3% | +4.3% | +8.2% | +8.2% | +6.0% | +6.7% | +8.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.5% | -2.8% | +0.5% | +1.0% | +0.8% | +5.3% | +2.4% | +0.1% | +1.2% | +4.3% | +1.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.